Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus

Marianne Pavel,Nicole Unger,Ivan Borbath,Sergio Ricci,Tsann-Long Hwang,Thomas Brechenmacher,Jinhee Park,Fabian Herbst,Jennifer L. Beaumont,Oliver Bechter

Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus

2016

Marianne Pavel
Nicole Unger
Ivan Borbath
Sergio Ricci
Tsann-Long Hwang
Thomas Brechenmacher
Jinhee Park
Fabian Herbst
Jennifer L. Beaumont
Oliver Bechter

Background/Aims An open-label, multi-center, expanded access study was conducted in patients with advanced neuroendocrine tumors (NET) treated with everolimus (10 mg/day) to assess safety and health-related quality of life (HRQOL).

Keywords:

Pharmacology
Lanreotide
Neuroendocrine tumors
Quality of life
Medicine
Everolimus
Expanded Access Study
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations